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To describe the characteristics and the outcome of primary Sjögren Syndrome (pSS)
associated arthritis and to compare the efficacy of different therapeutic regimen.
Methods
We conducted a retrospective study using Club Rhumatisme and Inflammation (CRI)
and French Internal Medicine Society (SNFMI) networks. All patients with a diagnosis
of pSS and at least one episode of clinical and/or echographic synovitis were included.
Patients with synovitis (cases) were compared to pSS patients without synovitis
(controls).
Results
57 patients (93% women) were included with a median age of 54 years [45–63].
Patients with synovitis had more frequently lymph node enlargement (12.3% vs. 1.8%,
p = .007) and a higher ESSDAI score (8 [6–12] vs. 2 [1–4], p < .0001). There was no
difference concerning CRP levels, rheumatoid factor and cyclic citrullinated peptide
(CCP)-antibodies positivity. Among 57 patients with synovitis, 101 various treatment
courses have been used during the follow-up of 40 [22.5–77] months. First treatment
course consisted in steroids alone (3.5%), steroids in association (79%) with
hydroxychloroquine (HCQ) (49%), methotrexate (MTX) (35%), rituximab (RTX) (5.3%)
or other immunosuppressive drugs (7%). HCQ, MTX, and RTX were associated with a
significant reduction of tender and swollen joint count, and a significant steroids-
sparing effect. No difference could be shown for the joint response between these
treatment regimens.
Conclusion
pSS articular manifestations may include synovitis which could mimic rheumatoid
arthritis but differ by the absence of structural damage. Even if the use of HCQ, MTX,
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